Michael Abrams

Chief Financial Officer at NRX Pharmaceuticals.

Raised on NRX Pharmaceuticals filings

$3.5M

of $3.5M offered across 1 Form D filing

Company

Biotech · Wilmington, DE

Drugs for suicidal bipolar depression and PTSD

Drugs for suicidal bipolar depression and PTSD

NRX Pharmaceuticals Form D filings
Filed	Security	Sold of offered	Filing
Mar 7, 2025	Option to acquire	$3.5M/ $3.5M	Form D

Also named on NRX Pharmaceuticals filings